Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Immobilized Rat ICOS / CD278 (C137S, C138S), His Tag (Cat. No. ICS-R52H9) at 5 μg/mL (100 μL/well) can bind Mouse B7-H2, Fc Tag (Cat. No. B72-M5258) with a linear range of 2-39 ng/mL (QC tested).
The purity of Human ICOS Protein, His Tag (Cat. No. ICS-H52Ha) is more than 90% and the molecular weight of this protein is around 52-62 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Izuralimab | XmAb-23104; XmAb-104 | Phase 2 Clinical | Xencor Inc | Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
Feladilimab | GSK-609; GSK-3359609 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma | Details |
Alomfilimab | KY-1044 | Phase 2 Clinical | Kymab Ltd | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Mycosis Fungoides | Details | |
Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Izuralimab | XmAb-23104; XmAb-104 | Phase 2 Clinical | Xencor Inc | Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
Feladilimab | GSK-609; GSK-3359609 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma | Details |
Alomfilimab | KY-1044 | Phase 2 Clinical | Kymab Ltd | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Mycosis Fungoides | Details | |
Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
This web search service is supported by Google Inc.